Ignite Creation Date:
2024-05-05 @ 5:27 PM
Last Modification Date:
2024-10-26 @ 9:32 AM
Study NCT ID:
NCT00456040
Status:
COMPLETED
Last Update Posted:
2007-04-04
First Post:
2007-04-02
Brief Title:
Characteristics of Patients With Amyloidosis Heart Failure Being Evaluated for a Heart Transplant
Sponsor:
Massachusetts General Hospital
Organization:
Massachusetts General Hospital
Study Overview
Official Title:
Characteristics of Patients With Systemic Amyloidosis and Severe Heart Failure Being Evaluated for a Sequential Cardiac and Autologous Stem Cell Transplantation
Status:
COMPLETED
Status Verified Date:
2007-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to describe the characteristics of patients with amyloidosis and severe heart failure being evaluated for cardiac and stem cell transplantation
Detailed Description:
Systemic amyloidosis is a progressive disease leading to organ failure and death Treatment has improved survival with stem-cell transplantation Unfortunately patients with amyloidosis and severe heart failure are not eligible for stem-cell transplantation
The average rate of survival for patients with amyloidosis who receive a heart transplant is decreased
Previous trials have raised the possibility that survival may be increased in patients with amyloidosis if chemotherapy and stem-cell transplantation is performed after a heart transplant
We plan to review data of patients with amyloidosis and heart failure who were being evaluated for a heart transplant
The average rate of survival for patients with amyloidosis who receive a heart transplant is decreased
Previous trials have raised the possibility that survival may be increased in patients with amyloidosis if chemotherapy and stem-cell transplantation is performed after a heart transplant
We plan to review data of patients with amyloidosis and heart failure who were being evaluated for a heart transplant
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None